Merck & Co
News/ News/ News/ Oncology/ Sales and Marketing
AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy
Phil Taylor
adjuvant, AstraZeneca, breast cancer, EU, Lynparza, Merck & Co, Oncology, targeted oncology
0 Comment
News/ News/ News/ Oncology/ R&D
Keytruda fluffs its lines in prostate, liver cancer trials
Phil Taylor
immuno-oncology, Keytruda, Liver cancer, Merck & Co, Oncology, Prostate cancer
0 Comment
News/ News/ News/ Oncology/ Sales and Marketing
Merck sees big lift in Keytruda sales, as Senate probes its taxes
Phil Taylor
Financial, Gardasil, Keytruda, Lagevrio, Merck & Co, tax, US
0 Comment
NewAmsterdam goes public to advance drug in abandoned class
Phil Taylor
cardiovascular, cholesterol, Merck & Co, NewAmsterdam Pharma, obicetrapib, R&D
0 Comment
After cough drug setback, Merck partners Hyfe’s tracking app
Phil Taylor
cough, digital, digital health, gefapixant, Hyfe, Merck & Co, partnering, Pfizer, ResApp Health
0 Comment
News/ News/ News/ Oncology/ R&D
Bid to expand Keytruda use in head and neck cancer therapy fails
Phil Taylor
head and neck cancer, immuno-oncology, Keytruda, Merck & Co, Oncology
0 Comment
News/ News/ News/ Oncology/ R&D
Disappointment as Lynparza fails colorectal cancer test
Phil Taylor
AstraZeneca, colorectal cancer, Lynparza, Merck & Co, Oncology, PARP inhibitor
0 Comment
News/ News/ News/ Oncology/ R&D
Merck buys into Orion prostate cancer therapy in $290m deal
Phil Taylor
Merck & Co, Oncology, Orion, partnering, Prostate cancer
0 Comment